Across TCGA pan-cancer cohorts, NIF3L1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NIF3L1 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NIF3L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NIF3L1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

STAD, LIHC, and HNSC are the cancer types where NIF3L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.074	0.667	<.001	39	view →
LIHC	DFS	Median	All	0.086	0.544	<.001	15	view →
HNSC	OS	Median	IV	0.081	0.733	<.001	12	view →
BLCA	DFS	Median	III,IV	1.000	0.269	.022	10	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NIF3L1 tumor-vs-normal RNA expression · all NIF3L1 data types